Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fipaxalparant - Horizon Therapeutics

Next Previous
Drug Profile

Fipaxalparant - Horizon Therapeutics

Alternative Names: CZN-001; HZN-825; SAR-100842

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Horizon Pharmaceuticals; Horizon Therapeutics plc
  • Class Amides; Antifibrotics; Benzene derivatives; Carboxylic acids; Ethers; Indenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse scleroderma; Idiopathic pulmonary fibrosis

Most Recent Events

  • 24 Feb 2025 Horizon Therapeutics terminates a phase I/II open-label extension trial for Diffuse scleroderma in USA, Argentina, Chile, Greece, Israel, Italy, Japan, Mexico, Poland, Portugal, Romania, Serbia, South Korea, Spain, United Kingdom, due to the parent trial (HZNP-HZN-825-301) meeting pre-defined criteria for futility (NCT05626751; EudraCT2021-006271-42)
  • 24 Feb 2025 Amgen terminates phase-II trials in Diffuse scleroderma in Serbia, Spain (PO) due to meeting pre-defined criteria for futility (NCT04781543)
  • 11 Feb 2025 Discontinued - Phase-II for Diffuse scleroderma in Switzerland, United Kingdom, Italy, Italy, Netherlands, Spain, Austria, Germany, Portugal, Poland, Mexico, South Korea, Israel, Greece, France, Argentina, USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top